Mim8与凝血因子VIII、FVIIa及活化凝血酶原复合物联合在凝血酶生成试验中的体外效应
本研究采用凝血酶生成试验(TGA),以组织因子(TF)或活化因子XI为激活剂,比较Mim8与FVIII的作用模式,并观察Mim8与FVIII、活化因子VII(FVIIa)及活化凝血酶原复合物(aPCC)混合的效应。结果显示,无抑制物患者中Mim8不干扰FVIII作用;有抑制物患者中Mim8与aPCC混合产生强协同效应,使凝血酶生成远超正常水平,而与FVIIa混合呈可控的相加效应,仅在TF触发时可见且不超过正常水平。
要点
- 无抑制物患者中,Mim8不干扰FVIII的作用模式。
- 有抑制物患者中,Mim8与aPCC混合产生强协同效应,凝血酶生成远超正常水平。
- Mim8与FVIIa混合呈可控相加效应,仅在TF触发时可见且不超过正常水平。
核心结论
- 研究结果支持对有FVIII抑制物且正在接受Mim8治疗的患者,使用获批临床剂量的FVIIa进行出血治疗。
- 研究结果提示,同时使用FVIII和Mim8管理突破性出血是安全的。
研究设计与样本
- 体外研究,采用凝血酶生成试验(TGA),以组织因子(TF)和活化因子XI为不同激活剂。
- 比较Mim8与凝血因子VIII(FVIII)的作用模式,并观察Mim8与FVIII、活化因子VII(FVIIa)及活化凝血酶原复合物(aPCC)混合的效应。
主要发现
- 无抑制物患者中,Mim8不干扰FVIII的作用模式。
- 有抑制物患者中,Mim8与aPCC混合产生强协同效应,导致凝血酶生成远超正常水平。
- 有抑制物患者中,Mim8与FVIIa混合产生更可控的相加效应,仅在使用TF作为触发剂时可见,且不超过正常凝血酶生成水平。
临床怎么用
- 作者结论支持对有FVIII抑制物且正在接受Mim8治疗的患者,使用获批临床剂量的FVIIa进行出血治疗。
- 作者结论提示,同时使用FVIII和Mim8管理突破性出血是安全的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mim8 is a novel antifactor IXa/antifactor X bispecific antibody in clinical development for prophylactic treatment of hemophilia A with and without inhibitors. Patients treated with Mim8 may need supplementary bleed treatment under certain conditions such as surgery or major trauma. OBJECTIVES: This study aimed to better understand the response of Mim8 in thrombin generation assays (TGAs) alone or in combination with other hemostatic proteins. METHODS: We used TGAs with different activators (tissue factor (TF) and activated factor XI) to better understand the similarities and differences between the mode of action of Mim8 and factor VIII (FVIII). Following this, we investigated the effects of mixing Mim8 with the main bleed treatment options for persons with hemophilia A with or without inhibitors: FVIII, activated factor VII (FVIIa), and activated prothrombin complex concentrates (aPCC). RESULTS: The results indicated that for patients without inhibitors, Mim8 does not interfere with FVIII's mode of action. For patients with inhibitors, Mim8 mixed with aPCC results in a strong synergistic effect causing thrombin generation far exceeding the normal levels. Contrary to this, mixing Mim8 with FVIIa results in a more controlled additive effect, visible only when using TF as a trigger, which does not exceed the normal level of thrombin generation. CONCLUSION: These findings support the use of approved clinical doses of FVIIa for bleed treatment of patients with FVIII inhibitors treated with Mim8. Additionally, the findings suggest that concomitant use of FVIII and Mim8 is safe for managing breakthrough bleeds.
引用
- Lund J, Jensen K, Burnier L, et al. In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays. J Thromb Haemost. 2023. PMID: 37037699. doi:10.1016/j.jtha.2023.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。